Table 3 The 20 top-selling biopharmaceutical products in 2017

From: Biopharmaceutical benchmarks 2018

RankProductSales, 2017 ($ billions)aCumulative sales, 2014–2017 ($ billions)Year first approvedCompanyPatent expirybBiosimilar version(s) approved
1Humira (adalimumab; anti-TNF)18.9462.62002AbbVie, Eisai2016 (US)
2018 (EU)
Halimatoz/Hefiya/Hyrimoz,Amgevita/Amjevita/Solymbic, Cyltezo, Imraldi
2Enbrel (etanercept; anti-TNF)8.3435.41998Amgen, Pfizer, Takeda Pharmaceuticals2015 (EU)
2028 (US)
Erelzi, Benepali
3Rituxan/MabThera(rituximab; anti-CD20)7.7829.11997Roche, Biogen Idec2013 (EU)
2016 (US)
Blitzima/Truxima, Ritemvia, Rituzena, Rixathon/Riximyo
4Remicade (infliximab; anti-TNF)7.7735.61998Johnson & Johnson, Merck, Mitsubishi Tanabe Pharma2015 (EU)
2018 (US)
Zessly, Ixifi, Renflexis/Flixabi, Inflectra/Remsima
5Herceptin (trastuzumab; anti-HER2)7.3927.11998Roche2014 (EU)
2019 (US)
Herzuma, Kanjinti, Trazimera, Ogivri, Ontruzant
6Avastin (bevacizumab; anti-VEGF)7.0427.02004Roche2017 (US)
2019 (EU)
Mvasi
7Lantus (insulin glargine)6.7227.42000Sanofi2014 (EU & US)Semglee, Lusduna, Abasaglar/Basaglar
8Eylea (aflibercept; anti-VEGF)5.9318.02011Regeneron, Bayer2020 (EU)
2021 (US)
 
9Opdivo (nivolumab; anti-PD-1 receptor)5.7911.42014Bristol-Myers Squibb, Ono Pharmaceutical2027 (US)
2026 (EU)
 
10Neulasta (pegfilgrastim)4.5320.12002Amgen, Kyowa Hakko Kirin2014 (US)
2015 (EU)
Fulphila
11Stelara (ustekinumab; anti-IL-12 & IL-23)4.0112.22009Janssen Cilag (Johnson & Johnson)2023 (US)
2024 (EU)
 
12Keytruda (pembrolizumab, anti-PD-1)3.815.72014Merck2036 (US)
2028 (EU)
 
13Prolia/Xgeva (denosumab, anti-RANKL)3.5411.62010Amgen2025 (US)
2022 (EU)
 
14Lucentis (ranibizumab; anti-VEGF)3.3814.32006Roche, Novartis2016 (EU & US) 
15Novolog/Novorapid (insulin aspart)3.3111.71999Novo Nordisk2015 (EU & US) 
16Soliris (eculizumab; anti–C5 complement protein)3.1410.72007Alexion Pharmaceuticals2021 (US)
2020 (EU)
 
17Simponi (golimumab; anti-TNF)2.949.72009Merck, Janssen, Mitsubishi Tanabe2024 (EU & US) 
18Humalog mix 50:50 (insulin lispro)2.8611.31996Eli Lilly2014 (US)
2015 (EU)
Insulin lispro Sanofi
19Xolair (omalizumab) anti-IgE2.758.72003Roche, Novartis2017 (EU & US) 
20Aranesp/Nesp (darbepoetin alfa)2.62102001Amgen, Kyowa Hakko Kirin2016 (EU)
2024 (US)
 
  1. aFinancial data from La Merie Business intelligence.
  2. bPatent data from various sources, including http://www.gabionline.net/Biosimilars/General/Biologicals-patent-expiries.HER2, human epidermal growth factor receptor 2; IgE, immunoglobulin E; IL, interleukin; PD-1, programmed cell death receptor 1; RANKL, receptor activator of nuclear factor-κB ligand; VEGF, vascular endothelial growth factor.